Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $4.2200 (-6.64%) ($4.2200 - $4.2200) on Wed. Dec. 1, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.4% (three month average) | RSI | 24 | Latest Price | $4.2200(-6.64%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.5% a day on average for past five trading days. | Weekly Trend | HTBX declines -6.4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) XBI(53%) ARKG(52%) ARKK(52%) IBUY(50%) ONLN(50%) | Factors Impacting HTBX price | HTBX will decline at least -1.2% in a week (0% probabilities). VIXM(-33%) VXX(-30%) UUP(-15%) TLT(-10%) XLU(-9%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.2% (StdDev 2.4%) | Hourly BBV | -1.7 () | Intraday Trend | 0% | | | |
|
Resistance Level | $4.81 | 5 Day Moving Average | $4.43(-4.74%) | 10 Day Moving Average | $4.43(-4.74%) | 20 Day Moving Average | $4.81(-12.27%) | To recent high | -42.8% | To recent low | 0% | Market Cap | $464m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |